STOCK TITAN

Virios Therapeutics Inc - VIRI STOCK NEWS

Welcome to our dedicated news page for Virios Therapeutics (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Virios Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Virios Therapeutics's position in the market.

Rhea-AI Summary
Virios Therapeutics halts sales under Capital on Demand Sales Agreement with JonesTrading due to market conditions and investor sentiment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.47%
Tags
none
-
Rhea-AI Summary
Virios Therapeutics, a biotech company focused on antiviral therapies, announced financial results for Q2 2023. The FDA expressed support for the safety of IMC-1 in treating fibromyalgia. The company plans to initiate a pharmacokinetic study and submit Phase 3 study protocols for FDA review. Enrollment for the first fibromyalgia Phase 3 study is expected to begin in mid-2024. Virios also plans to sponsor a second study for Long-COVID treatment. The company will meet with the FDA to discuss advancing IMC-2 into Phase 2 development for Long-COVID. Q2 2023 financial results show a decrease in research and development expenses and general administrative expenses. Net loss for Q2 2023 was $1.4 million. Virios Therapeutics has a cash balance of $4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.21%
Tags
-
Rhea-AI Summary
Virios Therapeutics, Inc. plans to initiate a pharmacokinetic and food effect study this year for its novel antiviral therapy, IMC-1, to treat fibromyalgia. The FDA has communicated that the chronic toxicology program studies appear adequate to support the safety of IMC-1. The Company will also resubmit a final Phase 3 program outline and study protocols for FDA review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.1%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences earnings
-
Rhea-AI Summary
Virios Therapeutics, Inc. announced that female patients with Long-COVID showed significant improvements in fatigue, pain, and symptoms of autonomic dysfunction when treated with a combination of valacyclovir and celecoxib. The improvements were statistically significant compared to a control group. The company plans to meet with the FDA to discuss further development of this treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.25%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.01%
Tags
none
Rhea-AI Summary
Virios Therapeutics submits final toxicology reports to the FDA for their Phase 3 proposal of IMC-1 as a treatment for fibromyalgia. The proposed program includes clinical studies, a safety trial, and a pharmacokinetic/food effect study. The company is awaiting FDA feedback.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
-
Rhea-AI Summary
Virios Therapeutics to report first quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.2%
Tags
Virios Therapeutics Inc

Nasdaq:VIRI

VIRI Rankings

VIRI Stock Data

9.87M
16.68M
9.71%
8.09%
1.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Alpharetta

About VIRI

innovative med concepts is an international trade and development company located in 1837 commons north drive, tuscaloosa, al, united states.